Your browser doesn't support javascript.
loading
Single dose pharmacokinetics of fenspiride hydrochloride: phase I clinical trial.
Montes, B; Catalan, M; Roces, A; Jeanniot, J P; Honorato, J M.
Afiliación
  • Montes B; Servicio de Farmacologia Clinica, Universidad de Navarra, Pampelona, Spain.
Eur J Clin Pharmacol ; 45(2): 169-72, 1993.
Article en En | MEDLINE | ID: mdl-7901024
The absolute bioavailability of fenspiride has been studied in twelve healthy volunteers. It was administered IV and orally in single doses of 80 mg fenspiride hydrochloride according to a randomised crossover pattern. Following IV administration, the plasma clearance of fenspiride was about 184 ml.min-1, and its apparent volume of distribution was moderately large (215 l). When given orally as a tablet, fenspiride exhibited fairly slow ab- sorption; the maximum plasma concentration (206 ng.ml-1) was achieved 6 h after administration. The absolute bioavailability was almost complete (90%). The tablet had slow release characteristics. The elimination half-life obtained from the plasma data was 14 to 16 h independent of the route of administration.
Asunto(s)
Buscar en Google
Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Compuestos de Espiro Tipo de estudio: Clinical_trials Límite: Adult / Humans / Male Idioma: En Revista: Eur J Clin Pharmacol Año: 1993 Tipo del documento: Article País de afiliación: España
Buscar en Google
Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Compuestos de Espiro Tipo de estudio: Clinical_trials Límite: Adult / Humans / Male Idioma: En Revista: Eur J Clin Pharmacol Año: 1993 Tipo del documento: Article País de afiliación: España